Bear of the Day: Centene (CNC)

Centene Corporation (CNC) unexpectedly withdrew its 2025 earnings guidance on July 2, citing an unforeseen shift in the health Insurance Marketplace characterized by higher-than-expected market morbidity and slower growth. This change is projected to result in a $1.8 billion shortfall in net risk adjustment revenues, equating to a $2.75 impact on 2025 adjusted diluted EPS, prompting Wall Street analysts to halve their consensus EPS to $3.55. In response, CNC is proactively adjusting 2026 rates to account for a higher morbidity baseline, while Wells Fargo downgraded the stock and significantly cut its price target from $72 to $30.

Analysis

Centene Corporation has withdrawn its 2025 earnings guidance due to a significant and unexpected deterioration in its Health Insurance Marketplace segment. This decision was prompted by actuarial data covering 72% of its Marketplace membership, which indicated higher-than-expected market morbidity and slower growth. The direct financial consequence is a projected $1.8 billion shortfall in net risk adjustment revenues, translating into a $2.75 negative impact on 2025 adjusted diluted EPS, with management anticipating further declines from the remaining states. In response, Wall Street has aggressively revised expectations, cutting the 2025 consensus EPS forecast in half to $3.55, and Wells Fargo downgraded the stock to Equal-Weight while slashing its price target from $72 to $30. While the company noted that its 2024 risk-adjusted results met expectations and its Medicare segments are outperforming, this is partially offset by rising cost pressures in its Medicaid business. Proactively, Centene is refiling its 2026 rates to reflect the higher morbidity baseline, signaling a defensive pricing strategy to mitigate future losses. The upcoming second-quarter earnings release on July 25 is now a critical event for gaining further clarity.

Key Decisions for Investors

• Investors should treat the upcoming July 25 earnings release as a pivotal event for clarity, as the full impact of market morbidity remains partially unquantified and management's detailed mitigation strategy is not yet fully articulated.
• The drastic reduction in 2025 earnings expectations, with a $2.75 EPS impact, necessitates a fundamental re-evaluation of valuation models to reflect both the immediate earnings shortfall and the longer-term implications of a more defensive pricing strategy for 2026.
• Given the diverging performance across segments, it is crucial to analyze the Q2 results for any signs of strength in the Medicare business potentially offsetting the significant headwinds from the Marketplace and rising costs in Medicaid.